Cure8 research brief
Noninvasive TUS can help detect small-bowel inflammation and stenosis in Crohn's disease with high specificity, potentially reducing the need for immediate invasive testing. However, its sensitivity varies by small-bowel segment, so negative TUS does not fully exclude disease.
Clinicians who evaluate and monitor patients with Crohn's disease (gastroenterologists, IBD specialists), researchers studying imaging diagnostics in IBD, and adult patients interested in noninvasive monitoring options.
This was a prospective, single-center study of 94 patients with Crohn's disease who had TUS the day before BAE. The authors report TUS sensitivity of 69% (terminal ileum) and 91% (proximal small bowel) for mucosal inflammation, with specificities of 94% and 82%, respectively.
For stenosis, reported sensitivities were 78% (terminal ileum) and 63% (proximal small bowel) with high specificities. The study also explored clinical factors (anastomotic involvement, prior bowel resection) associated with detectability on TUS but found no independent predictors on multivariable analysis.
Practical takeaway: TUS is a complementary, noninvasive assessment that performs well for ruling in disease (high specificity) but has segment-dependent sensitivity; clinicians may need additional evaluation (for example BAE or cross-sectional imaging) when clinical suspicion remains despite negative or equivocal TUS.
This classification and brief are grounded in the article abstract (prospective single-center study, n=94) published in Intestinal Research. The study used BAE as the reference standard. As a single-center study, findings may need replication in larger, multicenter cohorts before broad generalization.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests intestinal ultrasound findings early after diagnosis — especially achieving “transmural remission” within 3 months — may predict better 1-year outcomes (sustained steroid-free remission and less need...
Noninvasive tests at 3 months after ileocecal resection (ultrasound + fecal calprotectin) may identify patients at high risk of endoscopic recurrence by 6 months. That could help avoid or target postoperative endoscopy...
Capsule endoscopy can be helpful for small-bowel assessment in Crohn’s disease but carries a risk of retention when strictures are present. Retained capsules may be asymptomatic yet still require surgery, so better...
